Riskpilot← Back to searchSign inGet full accessBiosync Technology AB
ABBankruptOrg 5568927791Computer programming activities · NACE 6201Est. 20120 employees
Revenue 2020
SEK 0
EBITDA margin
—
+32% vs 2019
Equity ratio
-34.6%
Financial strength
Net profit 2020
SEK -213K
+17% vs 2019
| Revenue | SEK 0 | — |
| EBITDA | SEK -42K | +32% |
| Net profit | SEK -213K | +17% |
| Total assets | SEK 497K | -21% |
| Equity | SEK -172K | -2767% |
| Employees | 0 | — |
Legal name
Biosync Technology AB
Org number
5568927791
Legal form
Aktiebolag
NACE code
6201 · Computer programming activities
Founded
9 maj 2012
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2020-08-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva utveckling, forskning och försäljning avseende biosensorbaserad hård- och mjukvara samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenue | 1 571 | 394 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 466 | 190 | −234 | −62 | −42 |
| Depreciation & amort. | −92 | −276 | −276 | −138 | −138 |
| EBIT | 374 | −86 | −510 | −200 | −180 |
| Net financials | −7 | — | −26 | −59 | −33 |
| Profit before tax | 271 | 10 | −535 | −258 | −213 |
| Tax | −67 | −5 | −0 | −0 | −0 |
| Net profit | 204 | 5 | −535 | −258 | −213 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Total assets | 875 | 1 290 | 760 | 630 | 497 |
| Equity | 311 | 316 | −120 | −6 | −172 |
| Long-term debt | 0 | 592 | 592 | 600 | 600 |
| Short-term debt | 469 | 383 | 288 | 36 | 69 |
| Total debt | 469 | 975 | 880 | 636 | 669 |
EBITDA margin
-4200000.0%
This company
15.8%
Market median
-26582378% vs market
20162020
Equity ratio
-34.6%
This company
38.2%
Market median
-191% vs market
20162020
Return on equity
-21300000.0%
This company
18.4%
Market median
-115760970% vs market
20162020
Net profit margin
-21300000.0%
This company
8.1%
Market median
-262963063% vs market
20162020
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162020
Debt / equity
3.89×
This company
0.62×
Market median
-527% vs market
20162020
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-09-01 – 2019-08-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-09-01 – 2018-08-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-09-01 – 2017-08-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-09-01 – 2016-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
BL Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Biosync Technology AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Björn Lennart de Jounge | Chief Executive Officer | 0 companies |
| Aaron Ardiri | Deputy Board Member | 0 companies |